Skip to main content
. Author manuscript; available in PMC: 2012 Oct 15.
Published in final edited form as: J Immunol. 2011 Sep 14;187(8):4219–4228. doi: 10.4049/jimmunol.1100826

Figure 3. IFN-γ-independent SC tumor rejection requires IL-17.

Figure 3

IFN-γ KO mice were treated with either isotype antibody or anti-IL-17 antibody twice per week. Ad5E1 clone 2.1 tumor cells (5 × 104) were SC injected in the right flank. Tumor growth was observed three times per week. Data are the combined results of three independent experiments (N=15 mice/group/experiment).